Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/9138

3,3'-Dimethylbenzidine dihydrochloride: Target Organs and Levels of Evidence for TR-390

Toxicology and Carcinogenesis Studies of 3,3'-Dimethylbenzidine Dihydrochloride (CASRN 612-82-8) in F344/N Rats (Drinking Water Studies)

Chemical (Study Title)
CASRN		Peer Review DateRoute/Exposure LevelsStudy Laboratory
3,3'-Dimethylbenzidine dihydrochloride
612-82-8		04/25/1990Dosed-Water
RATS ONLY: 0,30,70,150 PPM (70,45,75,70 PER GROUP RESPECTIVELY)		Hazleton, Vienna

Levels of Evidence

Male Rats: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Skin: BASAL CELL ADENOMA 0/60 10/45 52/75 29/60 OR BASAL CELL CARCINOMA 0/60 1/45 4/75 2/60 COMBINED 0/60 11/45 54/75 30/60; SEBACEOUS GLAND ADENOMA 0/60 0/45 7/75 5/60; KERATOACANTHOMA 1/60 1/45 8/75 5/60; SQUAMOUS CELL PAPILLOMA 0/60 0/45 8/75 15/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 10/75 13/60 COMBINED 0/60 2/45 17/75 27/60
  • Zymbal Gland: ADENOMA 1/60 1/45 13/75 16/60 OR CARCINOMA 0/60 2/45 21/75 23/60 COMBINED 1/60 3/45 32/75 36/60
  • Preputial Gland: ADENOMA 2/60 4/45 4/75 8/60 OR CARCINOMA 0/60 0/45 2/75 1/60 COMBINED 2/60 4/45 6/75 9/60
  • Liver: NEOPLASTIC NODULE 0/60 0/45 29/75 26/60 OR CARCINOMA 0/60 0/45 12/75 12/60 COMBINED 0/60 0/45 35/75 33/60
  • Oral Cavity: SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 2/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 1/75 3/60 COMBINED 0/60 0/45 4/75 5/60
  • Large Intestines: ADENOMATOUS POLYP 0/60 0/45 7/75 10/60 OR ADENOCARCINOMA 0/60 0/45 3/75 15/60 COMBINED 0/60 0/45 10/75 23/75
  • Lung: ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 0/45 7/75 6/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/60 0/45 1/75 0/60 COMBINED 1/60 0/45 8/75 6/60
  • Mesothelium (Abdominal Cavity/Tunica Vaginalis): MESOTHELIOMA 0/60 0/45 3/75 4/60
May Have Been Related
  • Brain: GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 0/45 0/75 1/60; MENINGEAL SARCOMA 0/60 0/45 1/75 0/60
Non-Neoplastic Lesions
  • PREPUTIAL GLAND: HYPERPLASIA
  • LIVER: CYSTIC DEGENERATION; FOCAL CELLULAR ALTERATIONS
  • LUNG: HYPERPLASIA
  • ZYMBAL GLAND: HYPERPLASIA
Female Rats: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Skin: BASAL CELL ADENOMA 0/60 3/45 5/75 5/60 OR BASAL CELL CARCINOMA 0/60 0/45 5/75 4/60 COMBINED 0/60 3/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA 0/60 1/45 6/75 5/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 4/75 7/60 COMBINED 0/60 3/45 9/75 12/60
  • Zymbal Gland: ADENOMA 0/60 4/45 11/75 12/60 OR CARCINOMA 0/60 2/45 22/75 35/60 COMBINED 0/57 6/45 32/75 42/60
  • Clitoral Gland: ADENOMA 0/60 9/45 32/75 17/59 OR CARCINOMA 0/60 5/45 11/75 18/59 COMBINED 0/60 14/45 42/75 32/59
  • Liver: NEOPLASTIC NODULE 0/60 0/45 7/74 3/60 OR CARCINOMA 0/60 0/45 1/74 1/60 COMBINED 0/60 0/45 7/74 4/60
  • Oral Cavity: SQUAMOUS CELL PAPILLOMA 0/60 3/45 7/75 9/60 OR SQUAMOUS CELL CARCINOMA 0/60 1/45 2/75 4/60 COMBINED 0/60 3/45 9/75 13/60
  • Large Intestines: ADENOMATOUS POLYP 0/60 2/45 7/75 4/60 OR ADENOCARCINOMA 0/60 0/45 3/75 6/60 COMBINED 0/60 2/45 10/75 9/60
  • Mammary Gland: ADENOCARCINOMA 0/60 1/45 3/75 6/60
  • Lung: ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 1/45 3/74 3/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/60 0/45 0/74 1/60 COMBINED 1/60 1/45 3/74 4/60
May Have Been Related
  • Brain: ASTROCYTOMA 0/60 1/45 1/75 0/60; GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 1/45 0/75 0/60
  • Hematopoietic System: MONONUCLEAR CELL LEUKEMIA 1/60 3/45 6/75 4/60
Non-Neoplastic Lesions
  • CLITORAL GLAND: HYPERPLASIA
  • LIVER: CYSTIC DEGENERATION; FOCAL CELLULAR ALTERATIONS
  • LUNG: HYPERPLASIA
  • ZYMBAL GLAND: HYPERPLASIA